Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Therapy

EZH2i unlocks PDAC immune surveillance

Nature Cancer volume 4, pages 781–783 (2023)Cite this article

Subjects

Successful immune-mediated tumor control in pancreatic cancer is severely hampered by its dense desmoplastic stroma. New work shows that EZH2 inhibition relieves the suppressive effect of tumor stroma on pro-inflammatory chemokine expression after therapy-induced senescence, boosting NK and T cell recruitment and immunological tumor control.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: EZH2 inhibition unlocks full potential of therapy-induced senescence and immune surveillance in pancreatic cancer.

References

  1. Chibaya, L. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00553-8 (2023).

    Article  PubMed  Google Scholar 

  2. Waldman, A. D., Fritz, J. M. & Lenardo, M. J. Nat. Rev. Immunol. 20, 651–668 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bear, A. S., Vonderheide, R. H. & O’Hara, M. H. Cancer Cell 38, 788–802 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Petroni, G. et al. Cancer Cell 39, 310–345 (2021).

    Article  CAS  PubMed  Google Scholar 

  5. Ruscetti, M. et al. Cell 181, 424–441 e421 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ruscetti, M. et al. Science 362, 1416–1422 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Wang, L., Lankhorst, L. & Bernards, R. Nat. Rev. Cancer 22, 340–355 (2022).

    Article  CAS  PubMed  Google Scholar 

  8. Bracken, A. P. et al. Genes Dev. 21, 525–530 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Laugesen, A., Hojfeldt, J. W. & Helin, K. Mol. Cell 74, 8–18 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. LeBleu, V. S. et al. Nat. Med. 19, 1047–1053 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Shao, F. F., Chen, B. J. & Wu, G. Q. J. Leukoc. Biol. 110, 77–87 (2021).

    Article  CAS  PubMed  Google Scholar 

  12. Jones, P. A., Ohtani, H., Chakravarthy, A. & De Carvalho, D. D. Nat. Rev. Cancer 19, 151–161 (2019).

    Article  CAS  PubMed  Google Scholar 

  13. Sun, S. et al. Biochim. Biophys. Acta Rev. Cancer 1877, 188700 (2022).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Institute of Cancer Research, London, UK

    Helene Damhofer & Kristian Helin

Authors
  1. Helene Damhofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kristian Helin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristian Helin.

Ethics declarations

Competing interests

K.H. is a co-founder of Dania Therapeutics and a scientific advisor for Hannibal Innovation. He was recently a scientific advisor for Inthera Bioscience and MetaboMed. H.D. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Damhofer, H., Helin, K. EZH2i unlocks PDAC immune surveillance. Nat Cancer 4, 781–783 (2023). https://doi.org/10.1038/s43018-023-00562-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00562-7

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer